PL EN


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
Czasopismo
2008 | 3 | 3 | 257-270
Tytuł artykułu

Vascular abnormalities and low-grade chronic inflammation in women with polycystic ovary syndrome: Relationships with insulin resistance, obesity and hyperandrogenemia

Treść / Zawartość
Warianty tytułu
Języki publikacji
EN
Abstrakty
EN
Polycystic ovary syndrome (PCOS) is possibly the most common endocrinopathy of reproductive age, characterized by hyperandrogenism and oligomenorrhea. Additionally, approximately one-third to one-half of all women and adolescent girls with PCOS tend to fulfill many of the metabolic syndrome criteria, and many view PCOS as a premetabolic syndrome condition, predisposing to a high risk for cardiovascular disease. Endothelial dysfunction, impaired arterial structure, or proinflammatory markers are early features of atherosclerosis, and can be used as surrogate indicators of future coronary artery disease in women with PCOS. However, as the latest studies show, these symptoms are the result of deleterious effects that cardiovascular risk factors, in particular insulin resistance and obesity, produce on the vascular wall, rather than to the presence of PCOS per se. The relationship between hyperandrogenemia and the risk of cardiovascular disease is controversial and needs to be clarified. Further research is warranted to understand the pathogenesis of cardiovascular disease in PCOS, and to identify subtypes of PCOS in which the presence of cardiovascular risk factors may result in increased cardiovascular events, leading to high morbidity or mortality rates caused by cardiovascular disease.
Wydawca
Czasopismo
Rocznik
Tom
3
Numer
3
Strony
257-270
Opis fizyczny
Daty
wydano
2008-09-01
online
2008-07-10
Twórcy
autor
  • Department of Internal Medicine, Clinic of Endocrinology, University of Medicine and Pharmacy “Iuliu Hatieganu”, 400349, Cluj-Napoca, Romania , ioanamanaila@yahoo.com
  • Department of Internal Medicine, Clinic of Endocrinology, University of Medicine and Pharmacy “Iuliu Hatieganu”, 400349, Cluj-Napoca, Romania
  • Department of Internal Medicine, Clinic of Endocrinology, University of Medicine and Pharmacy “Iuliu Hatieganu”, 400349, Cluj-Napoca, Romania
autor
  • Clinic of Obstetrics and Gynaecology, 400124, Cluj-Napoca, Romania
Bibliografia
  • [1] Cussons A.J., Stuckey B.G.A., Watts G.F., Cardiovascular disease in the polycystic ovary syndrome: New insights and perspectives, Atherosclerosis, 2006, 185, 227–239 http://dx.doi.org/10.1016/j.atherosclerosis.2005.10.007[Crossref]
  • [2] Azziz R., Nestler J., Dewailly D., Androgen excess disorders in women: polycystic ovary syndrome and other disorders, 2nd ed., 2006, Humana Press
  • [3] Tarkun I., Arslan B.C., Cantürk Z., Türemen E., Sahin T., Duman C., Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation, J. Clin. Endocrinol. Metab., 2004, 89, 5592–5596 http://dx.doi.org/10.1210/jc.2004-0751[Crossref]
  • [4] Essah P., Wickham E., Nestler J., The metabolic syndrome in polycystic ovary syndrome, Clin. Obstretics and Gynecology, 2007, 1, 205–225 http://dx.doi.org/10.1097/GRF.0b013e31802f3547[Crossref]
  • [5] Lorenz L., Wild R., Polycystic ovarian syndrome: an evidence-based approach to evaluation and management of diabetes and cardiovascular risks for today’s clinician, Clin. Obstretics and Gynecology, 2007, 1, 226–243 http://dx.doi.org/10.1097/GRF.0b013e31802f5197[Crossref]
  • [6] Hoffman L.K., Ehrmann D.A., Cardiometabolic features of polycystic ovary syndrome, Nat. Clin. Pract. Endocrinol. Metab., 2008, 4, 215–222 http://dx.doi.org/10.1038/ncpendmet0755[Crossref]
  • [7] Shaw L.J., Bairey Merz C.N., Azziz R., Stanczyk F.Z., Sopko G., Braunstein G.D., et al, Post-Menopausal Women with a History of Irregular Menses and Elevated Androgen Measurements at High Risk for Worsening Cardiovascular Event-Free Survival: Results from the National Institutes of Health-National Heart, Lung, and Blood Institute Sponsored Women’s Ischemia Syndrome Evaluation, J. Clin. Endocrin.Metab., 2008, 93, 1276–1284 http://dx.doi.org/10.1210/jc.2007-0425[Crossref]
  • [8] Calles-Escandon J., Cipolla M., Diabetes and endothelial dysfunction: a clinical perspective, Endocrine Reviews. 2001, 22, 36–52 http://dx.doi.org/10.1210/er.22.1.36[Crossref]
  • [9] Caballero E., Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease, Obesity Research, 2003, 11, 1278–1289 http://dx.doi.org/10.1038/oby.2003.174[Crossref]
  • [10] Meyer C., McGrath B., Cameron J., Kotsopoulos D., Teede H.J., Vascular dysfunction and metabolic parameters in polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 2005, 90, 4630–4635 http://dx.doi.org/10.1210/jc.2004-1487[Crossref]
  • [11] Verma S., Anderson T.J., Fundamentals of endothelial function for the clinical cardiologist, Circulation, 2002, 105, 546–549 http://dx.doi.org/10.1161/hc0502.104540[Crossref]
  • [12] Quyyumi A.A., Endothelial function in health and disease: new insights into the genesis of cardiovascular disease, Am. J. Med., 1998, 105, 32S–39S http://dx.doi.org/10.1016/S0002-9343(98)00209-5[Crossref]
  • [13] Kravariti M., Naka K.K., Kalantaridou S.N., Kazakos N., Katsouras C.S., Makrigiannakis A., et al., Predictors of endothelial dysfunction in young women with polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 2005, 90, 5088–5095 http://dx.doi.org/10.1210/jc.2005-0151[Crossref]
  • [14] Orio F.J., Palomba S., Cascella T., De Simone B., Di Biase S., Russo T., et al., Early impairment of endothelial structure and function in young normalweight women with polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 2004, 89, 4588–4593 http://dx.doi.org/10.1210/jc.2003-031867[Crossref]
  • [15] Diamanti-Kandarakis E., Alexandraki K., Protogerou A., Piperi C., Papamichael C., Aessopos A., et al., Metformin administration improves endothelial function in women with polycystic ovary syndrome, Eur. J. Endocrinol., 2005, 152, 749–756 http://dx.doi.org/10.1530/eje.1.01910[Crossref]
  • [16] Tarkun I., Cetinarsian B., Turemen E., Sahin T., Canturk Z., Komsuoglu B., Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial dysfunction in non-obese young women with polycystic ovary syndrome, Eur. J. Endocrinol., 2005, 153, 115–21 http://dx.doi.org/10.1530/eje.1.01948[Crossref]
  • [17] Sorensen M.B., Frankst S., Robertson C., Penemm D.J., Collins P., Severe endothelial dysfunction in young women with polycystic ovary syndrome is only partially explained by known cardiovascular risk factors, Clin. Endocrinol., 2006, 65, 655–659 http://dx.doi.org/10.1111/j.1365-2265.2006.02645.x[Crossref]
  • [18] Paradisi G., Steinberg H.O., Hempfling A., Cronin J., Hook G., Shepard M.K. et al., Polycystic ovary syndrome is associated with endothelial dysfunction, Circulation, 2001, 103, 1410–1415 [Crossref]
  • [19] Paradisi G., Steinberg H.O., Shepard M.K., Hook G., Baron A.D., Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 2003, 88, 576–580 http://dx.doi.org/10.1210/jc.2002-020386[Crossref]
  • [20] Kelly C.J., Speirs A., Gould G.W., Petrie J.R., Lyalll H., Connell J.M.C., Altered vascular function in young women with polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 2002, 87, 742–746 http://dx.doi.org/10.1210/jc.87.2.742[Crossref]
  • [21] Bickerton A.S., Clark N., Meeking D., Shaw K.M., Crook M., Lumb P., et al, Cardiovascular risk in women with polycystic ovarian syndrome (PCOS), J. Clin. Pathol. 2005, 58, 151–154 http://dx.doi.org/10.1136/jcp.2003.015271[Crossref]
  • [22] Carmassi F., Negri F.D., Fioriti R., De Giorgi A., Giannarelli C., Fruzzetti F., et al, Insulin resistance causes impaired vasodilation and hypofibrinolysis in young women with polycystic ovary syndrome, Thrombosis Research, 2005, 116, 207–214 http://dx.doi.org/10.1016/j.thromres.2004.11.026[Crossref]
  • [23] Verma S., Buchanan M.R., Anderson T.J., Endothelial function testing as a biomarker of vascular disease, Circulation, 2003, 108, 2054–2059 http://dx.doi.org/10.1161/01.CIR.0000089191.72957.ED[Crossref]
  • [24] Nacul A.P., Andrade C.D., Schwarz P., Homem de Bittencourt Jr P.I., Spritzer P.M., Nitric oxide and fibrinogen in polycystic ovary syndrome: associations with insulin resistance and obesity, Europ. J. Obstet. Gynecol., 2007, 133, 191–196 http://dx.doi.org/10.1016/j.ejogrb.2006.09.009[Crossref]
  • [25] Dubin D., Pratt R.E., Cooke J.P., Dzau V.J., Endothelin, a potent vasoconstrictor, is a vascular smooth muscle mitogen, J. Vasc. Med. Biol., 1989, 1, 13–16
  • [26] Diamanti-Kandarakis E., Spina G., Kouli C., Migdalis I., Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy, J. Clin. Endocrinol. Metab., 2001, 86, 4666–4673 http://dx.doi.org/10.1210/jc.86.10.4666[Crossref]
  • [27] Orio F.J., Palomba S., Cascella T., De Simone B., Manguso F., Savastano S., et al., Improvement in endothelial structure and function after metformin treatment in young normal-weigt women with polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 2005, 90, 6072–6076 http://dx.doi.org/10.1210/jc.2005-0965[Crossref]
  • [28] Talbott E.O., Guzick D.S., Sutton-Tyrrell K., McHugh-Pemu K.P., Zborowski J.V., Remsberg K.E., et al., Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women, Arterioscler. Thromb. Vasc. Biol., 2000, 20, 2414–2421 [Crossref]
  • [29] Vural B., Caliskan E., Turkoz E., Kilic T., Demirci A., Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome, Hum. Reprod., 2005, 20, 2409–13 http://dx.doi.org/10.1093/humrep/dei100[Crossref]
  • [30] Carmina E., Orio F., Palomba S., Longo R.A., Cascella T., Colao A., et al., Endothelial dysfunction in PCOS: role of obesity and adipose hormones, Am. J. Medicine., 2006, 119, 356.e1–356.e6 http://dx.doi.org/10.1016/j.amjmed.2005.10.059[Crossref]
  • [31] Christian R.C., Dumesic D.A., Behrenbeck T., Oberg A.L., Sheedy II P.F., Fitzpatrick L.A., Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 2003, 88, 2562–2568 http://dx.doi.org/10.1210/jc.2003-030334[Crossref]
  • [32] Talbott E.O., Zborowski J.V., Rager J.R., Boudreaux M.Y., Edmundowicz D.A., Guzick D.S., Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 2004, 89, 5454–5461 http://dx.doi.org/10.1210/jc.2003-032237[Crossref]
  • [33] Meyer C., McGrath B.P., Teede H.K., Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease, J. Clin. Endocrinol. Metab., 2005, 90, 5711–5716 http://dx.doi.org/10.1210/jc.2005-0011[Crossref]
  • [34] Kershaw E.E., Flier J.S., Adipose tissue as an endocrine organ, J. Clin. Endocrinol. Metab., 2004, 89, 2548–2556 http://dx.doi.org/10.1210/jc.2004-0395[Crossref]
  • [35] Zhang Y., Yang Y., Hong J., Gu W., Shen C., Xu M., et al., Elevated serum levels of Interleukin-18 are associated with insulin resistance in women with polycystic ovary syndrome, Endocrine, 2006, 29, 3, 419–423 http://dx.doi.org/10.1385/ENDO:29:3:419[Crossref]
  • [36] Escobar-Morreale H.F., Botella-Carretero J.I., Villuendas G., Sancho J., San Millan J.L., Serum interleukin-18 concentrations are increased in the polycystic ovary syndrome: relationship to insulin resistance and to obesity, J. Clin. Endocrinol. Metab., 2004, 89, 806–811 http://dx.doi.org/10.1210/jc.2003-031365[Crossref]
  • [37] Linscheid P., Seboek D., Nylen E.S., Langer I., Schlatter M., Becker K.L., et al., In vitro and in vivo calcitonin I gene expression in parenchymal cells: a novel product of human adipose tissue, Endocrinology, 2003, 144, 5578–5584 http://dx.doi.org/10.1210/en.2003-0854[Crossref]
  • [38] Linscheid P., Seboek D., Schaer D.J., Zulewski H., Keller U., Muller B., Expression and secretion of procalcitonin and calcitonin gene-related peptide by adherent monocytes and by macrophageactivated adipocytes, Crit. Care. Med., 2004, 32, 1715–1721 http://dx.doi.org/10.1097/01.CCM.0000134404.63292.71[Crossref]
  • [39] Pai J.K., Pischon T., Ma J., Manson J.E., Hankinson S.E., Joshipura K., et al., Inflammatory markers and the risk of coronary heart disease in men and women, N. Engl. J. Med., 2004, 351, 2599–2610 http://dx.doi.org/10.1056/NEJMoa040967[Crossref]
  • [40] Danesh J., Wheeler J.G., Hirschfield G.M., Eda S., Eiriksdottir G., Rumley A., et al., C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease, N. Engl. J. Med., 2004, 350, 1387–1397 http://dx.doi.org/10.1056/NEJMoa032804[Crossref]
  • [41] Yudkin J.S., Kumari M., Humphries S.E., Mohamed-Ali V., Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?, Atherosclerosis., 2000, 148:209–14 http://dx.doi.org/10.1016/S0021-9150(99)00463-3[Crossref]
  • [42] Olszanecka-Glinianowicz M., Banas M., Zahorska-Markiewicz B., Janowska J., Kocelak P., Madej P., et al., Is the polycystic ovary syndrome associated with chronic inflammation per se?, Eur. J. Obstet. Gynecol. Reprod. Biol., 2007, 133, 197–202 http://dx.doi.org/10.1016/j.ejogrb.2006.10.037[Crossref]
  • [43] Blankenberg, S., Tiret L., Bickel C., Peetz D., Cambien F., Meyer J., et al., Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina, Circulation, 2002, 106, 24–30 http://dx.doi.org/10.1161/01.CIR.0000020546.30940.92[Crossref]
  • [44] Esposito K., Pontillo A., Ciotola M., Di Palo C., Grella E., Nicoletti G., et al., Weight loss reduces interleukin-18 levels in obese women, J. Clin. Endocrinol. Metab., 2002, 87, 3864–3866 http://dx.doi.org/10.1210/jc.87.8.3864[Crossref]
  • [45] Devaraj S., Xu D.Y., Jialal I., C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aorthic endothelial cells: implications for the metabolic syndrome and atherothrombosis, Circulation, 2003, 107, 398–404 http://dx.doi.org/10.1161/01.CIR.0000052617.91920.FD[Crossref]
  • [46] Wang C.H., Li S.H., Weisel R.D., Fedak P.W., Dumont A.S., Szmitko P., et al., C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle, Circulation, 2003, 107, 1783–1790 http://dx.doi.org/10.1161/01.CIR.0000061916.95736.E5[Crossref]
  • [47] Kelly C.C., Lyah H., Petrie J.R., Gould G.W., Connell J.M., Sattar N., Low grade chronic inflammation in women with polycystic ovarian syndrome, J. Clin. Endocrinol. Metab., 2001, 86, 2453–2455 http://dx.doi.org/10.1210/jc.86.6.2453[Crossref]
  • [48] Talbott E.O., Zborowski J.V., Boudreaux M.Y., McHugh-Pemu K.P., Sutton-Tyrrell K., Guzick D.S., The relationship between C-reactive protein and carotid intima-media wall thickness in middle-aged women with polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 2004, 89, 6061–6067 http://dx.doi.org/10.1210/jc.2003-032110[Crossref]
  • [49] Orio F. Jr., Palomba S., Cascella T., Di Biase S., Manguso F., Tauchmanova L., et al., The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 2005, 90, 2–5 http://dx.doi.org/10.1210/jc.2004-0628[Crossref]
  • [50] Morin-Papunen L., Rautio K., Ruokonen A., Hedeberg P., Puukka M., Tapanainen J.S., Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 2003, 88, 4649–4654 http://dx.doi.org/10.1210/jc.2002-021688[Crossref]
  • [51] Diamanti-Kandarakis E., Paterakis T., Alexandraki K., Piperi C., Aessopos A., Katsikis I., et al., Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin, Hum. Reprod., 2006, 21, 1426–1431 http://dx.doi.org/10.1093/humrep/del003[Crossref]
  • [52] Diamanti-Kandarakis E., Alexandraki K., Piperi C., Protogerou A., Katsikis I., Paterakis T., et al., Inflammatory and endothelial markers in women with polycystic ovary syndrome, Eur. J. Clin. Invest., 2006, 36, 691–697 http://dx.doi.org/10.1111/j.1365-2362.2006.01712.x[Crossref]
  • [53] Ibanez L., Jaramillo A.M., Ferrer A., de Zegher F., High neutrophil count in girls and women with hyperinsulinaemic hyperandrogenism: normalization with metformin and flutamide overcomes the aggravation by oral contraception, Hum. Reprod., 2005, 20, 2457–2462 http://dx.doi.org/10.1093/humrep/dei072[Crossref]
  • [54] Orio F., Manguso F., Di Biase S., Falbo A., Giallauria F., Labella D., et al., Metformin administration improves leukocyte count in women with polycystic ovary syndrome: a 6-month prospective study, Eur. J. Endocrinol., 2007, 157, 69–73 http://dx.doi.org/10.1530/EJE-07-0133[Crossref]
  • [55] Steinberg H.O., Baron A.D., Vascular function, insulin resistance and fatty acids, Diabetologia, 2002, 45, 623–634 http://dx.doi.org/10.1007/s00125-002-0800-2[Crossref]
  • [56] Caballero E., Metabolic and vascular abnormalities in subjects at risk for type 2 diabetes: the early start of a dangerous situation, Archives of Medical Research, 2005, 36, 241–249 http://dx.doi.org/10.1016/j.arcmed.2005.03.013[Crossref]
  • [57] Diamanti-Kandarakis E., Paterakis T., Kandarkis H.A., Indices of low-grade inflammation in polycystic ovary syndrome, Ann. N.Y. Acad. Sci., 2006, 1092, 175–186 http://dx.doi.org/10.1196/annals.1365.015[Crossref]
  • [58] Mohlig M., Spranger J., Osterhoff M., Ristow M., Pfeiffer A.F.H., Schill T., et al, The polycystic ovary syndrome per se is not associated with increased chronic inflammation, Eur. J.Endocrinol., 2004, 150, 525–532 http://dx.doi.org/10.1530/eje.0.1500525[Crossref]
  • [59] Puder J.J., Varga S., Kraenzlin M., De Geyter C., Keller U., Muller B., Central fat excess in polycystic ovary syndrome: reltion to low-grade inflammation and insulin resistance, J. Clin. Endocrinol. Metab., 2005, 90, 6014–6021 http://dx.doi.org/10.1210/jc.2005-1002[Crossref]
  • [60] Kearney M.T., Duncan E.R., Kahn M., Wheatcroft S.B., Insulin resistance and endothelial cell dysfunction: studies in mammalian models, Exp Physiol, 2008, 93, 158–163 http://dx.doi.org/10.1113/expphysiol.2007.039172[Crossref]
  • [61] Katusic Z., Vascular endothelial dysfunction: does tetrahydrobiopterin play a role?, Am. J. Physiol. Heart Circ. Physiol., 2001, 281, H981–H986
  • [62] Nystrom T., Nygren A., Sjoholm A., Tetra-hydrobiopterin increases insulin sensitivity in patients with type 2 diabetes and coronary heart disease, Am. J. Physiol. Endocrinol. Metab., 2004, 287, E919–E925 http://dx.doi.org/10.1152/ajpendo.00046.2004[Crossref]
  • [63] Carvalheira J.B.C., Calegari V.C., Zecchin HG., Nadruz V., Guimaraes R.B., Ribeiro E.B., et al., The crosstalk between insulin and angiotensin and insulin differentially affects phosphatidylinositol 3-kinase-and mitogen-activated protein kinasemediated signaling in rat heart: implications for insulin resistance, Endocrinology, 2003, 144, 5604–5614 http://dx.doi.org/10.1210/en.2003-0788[Crossref]
  • [64] Andreozzi F., Laratta E., Sciacqua A., Perticone F., Sesti G., Angiotensin II impairs the insulin signaling pathaway promoting production of nitric oxide by inducing phosphorylation of insulin receptor substrate-1 on Ser 312 and Ser 616 in human umbilical vein endothelial cells, Circulation Research, 2004, 94, 1211–1218 http://dx.doi.org/10.1161/01.RES.0000126501.34994.96
  • [65] Piatti P.M., Monti L.D., Galli L., Fragasso G., Valsecchi G., Conti M., et al., Relationship between endothelin-1 concentrations and metabolic alterations typical of the insulin resistance syndrome, Metabolism, 2000, 49,748–752 http://dx.doi.org/10.1053/meta.2000.6257
  • [66] Kim Jeong-a, Montagnani M., Koh K.K., Quon M.J., Reciprocal relationship between insulin resistance and endothelial dysfunction: molecular pathophysiological mechanisms, Circulation, 2006, 113, 1888–1904 http://dx.doi.org/10.1161/CIRCULATIONAHA.105.563213[Crossref]
  • [67] Rosano G.M., Sheiban I., Massaro R., Pagnotta P., Marazzi G., Vitale C., et al., Low testosterone levels are associated with coronary artery disease in male patients with angina, Int. J. Impot. Res., 2007, 19, 176–182 http://dx.doi.org/10.1038/sj.ijir.3901504[Crossref]
  • [68] Vryonidou A., Papatheodorou A., Tavridou A., Terzi T., Loi V., Vatalas I.A., et al., Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 2005, 90, 2740–2746 http://dx.doi.org/10.1210/jc.2004-2363[Crossref]
  • [69] Dagre A., Lekakis J., Mihas C., Protogerou A., Thalassinou L., Tryfonopoulos D., et al., Association of dehydroepiandrosterone-sulfate with endothelial function in young women with polycystic ovary syndrome, Eur. J. Endocrinol., 2006, 154, 883–890 http://dx.doi.org/10.1530/eje.1.02153[Crossref]
  • [70] Worboys S., Kotsopoulos D., Teede H., McGrath B., Davis S.R., Evidence that parenteral testosterone therapy may improve endothelium-dependent and-independent vasodilation in postmenopausal women already receiving estrogen, J. Clin. Endocrinol. Metab., 2001, 86, 158–161 http://dx.doi.org/10.1210/jc.86.1.158[Crossref]
  • [71] Zhang Z., Wang L., Dou Y., Zhao J., Jiang T., Qiao Z., et al., Testosterone and estradiol modulate TNFalpha-induced expression of adhesion molecules in endothelial cells, Methods Find. Exp. Clin. Pharmacol., 2002, 24, 125–30 http://dx.doi.org/10.1358/mf.2002.24.3.802295[Crossref]
  • [72] McChrohon J.A., Jessup W., Handelsmann D.J., Celermajer D.S., Androgen exposure increases human monocyte adhesion to vascular endothelium and endothelial cell expression of vascular cell adhesion molecule-1, Circulation, 1999, 99, 2317–2322 [Crossref]
  • [73] Death A.K., McGrath K., Sader M., Nakhla S., Jessup W., Handelsman D.J., et al. Dihydrotestosterone promotes vascular cell adhesion molecule-1 expression in male human endothelial cells via a nuclear factor-?B-dependent patway, Endocrinology, 2004, 145,1889–1897 http://dx.doi.org/10.1210/en.2003-0789
  • [74] Gooren L.J., Giltay E.J., Review of studies of androgen treatment of female-to-male transsexuals: effects and risks of administration of androgens to females, J. Sex. Med., 2008, 5, 765–76 http://dx.doi.org/10.1111/j.1743-6109.2007.00646.x[Crossref]
  • [75] Elbers J.M., Giltay E.J., Teerlink T., Scheffer P.G., Asscheman H., Seidell J.C., et al., Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects, Clin. Endocrinol. (Oxf), 2003, 58, 562–71 http://dx.doi.org/10.1046/j.1365-2265.2003.01753.x[Crossref]
  • [76] Berra M., Armillotta F., D’Emidio L., Costantino A., Martorana G., Pelusi G., et al., Testosterone decreases adiponectin levels in female to male transsexuals, Asian J. Androl., 2006, 8, 725–729 http://dx.doi.org/10.1111/j.1745-7262.2006.00204.x[Crossref]
  • [77] McCredie R.J., McCrohon J.A., Turner L., Griffiths K.A., Handelsman D.J., Celermajer D.S., Vascular reactivity is impaired in genetic females taking high-dose androgens, J. Am. Coll. Cardiol., 1998, 32, 1331–1335 http://dx.doi.org/10.1016/S0735-1097(98)00416-1[Crossref]
  • [78] Simoncini T., Mannella P., Fornari L., Varone G., Caruso A., Genazzani A.R., Dehydroepiandrosterone modulates endothelial nitric oxide synthesis via direct genomic and nongenomic mechanisms, Endocrinology, 2003, 144, 3449–3455 http://dx.doi.org/10.1210/en.2003-0044[Crossref]
  • [79] Williams M.R.I., Ling S., Dawood T., Hshimura K., Dai A., Li H., et al., Dehydroepiandrosterone inhibits human vascular smooth muscle cell proliferation independent of ARs and ERs, J. Clin. Endocrinol. Metab., 2002, 87, 176–181 http://dx.doi.org/10.1210/jc.87.1.176[Crossref]
  • [80] Liu D., Dillon J.S., Dehydroepiandroterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor, The Journal of Biological Chemistry, 2002, 24, 21379–21388 http://dx.doi.org/10.1074/jbc.M200491200[Crossref]
  • [81] Liu D., Dillon J.S., Dehydroepiandroterone stimulates nitric oxide release in vascular endothelial cells: evidence for a cell surface receptor, Steroids, 2004, 69, 279–89 http://dx.doi.org/10.1016/j.steroids.2004.02.004[Crossref]
  • [82] Formoso G., Chen H., Kim J., Montagnani M., Consoli A., Quon M.J., Dehydroepiandroterone mimics acute actions of insulin to stimulate production of both nitric oxide and endothelin 1 via distinct phosphatidylinositol 3-kinase and mitogenactivated protein kinase-dependent pathways in vascular endothelium, Molecular Endocrinology, 2006, 20, 1153–1163 http://dx.doi.org/10.1210/me.2005-0266
  • [83] Ibanez L., de Zegher F., Ethinylestradiol-drospire-none, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity, J. Clin. Endocrinol. Metab., 2004, 89, 592–1597
  • [84] Cho L.W., Randeva H.S., Atkin S.L., Cardiometabolic aspects of polycystic ovarian syndrome, Vasc. Health Risk Manag., 2007, 3, 55–63
  • [85] Ouedraogo R., Gong Y., Berzins B., Wu X., Mahadev K., Hough K., et al., Adiponectin deficiency increases leukocyte-endothelium interactions via upregulation of endothelial cell adhesion molecules in vivo, J. Clin. Investig., 2007, 117, 1718–1726 http://dx.doi.org/10.1172/JCI29623[Crossref]
  • [86] Escobar-Morreale H.F., Villuendas G., Botella-Carretero J.I., Álvarez-Blasco F., Sanchón R., Luque-Ramírez M., Adiponectin and resistin in PCOS: a clinical, biochemical and molecular genetic study, Human Reproduction, 2006, 21, 2257–2265 http://dx.doi.org/10.1093/humrep/del146[Crossref]
  • [87] Ardawi M.S., Rouzi A.A., Plasma adiponectin and insulin resistance in women with polycystic ovary syndrome, Fertil. Steril., 2005, 83, 1708–1716 http://dx.doi.org/10.1016/j.fertnstert.2004.11.077[Crossref]
  • [88] Ducluzeau P.H., Cousin P., Malvoisin E., Bornet H., Vidal H., Laville M., et al., Glucose-to-insulin ratio rather than sex hormone-binding globulin and adiponectin levels is the best predictor of insulin resistance in nonobese women with polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 2003, 88, 3626–3631 http://dx.doi.org/10.1210/jc.2003-030219[Crossref]
  • [89] Gulcelik N.E., Aral Y., Serter R., Koc G., Association of hypoadiponectinemia with metabolic syndrome in patients with polycystic ovary syndrome, J. Natl. Med. Assoc., 2008, 100, 64–68
  • [90] Bik W., Baranowska-Bik A., Wolinska-Witort E., Chmielowska M., Martynska L., Baranowska B., The relationship between metabolic status and levels of adiponectin and ghrelin in lean women with polycystic ovary syndrome, Gynecol. Endocrinol., 2007, 23, 325–331 http://dx.doi.org/10.1080/09513590701260169[Crossref]
  • [91] Escobar-Moreale H.F., San Millan J.L., Abdominal adiposity and the polycystic ovary syndrome, Trends in Endocrinology and Metabolism, 2007, 18, 266–272 http://dx.doi.org/10.1016/j.tem.2007.07.003[Crossref]
Typ dokumentu
Bibliografia
Identyfikatory
Identyfikator YADDA
bwmeta1.element.-psjd-doi-10_2478_s11536-008-0044-8
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.